argenx Stock Forecast, Price & News

-2.14 (-0.68 %)
(As of 06/23/2021 02:05 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,262 shs
Average Volume195,195 shs
Market Capitalization$16.09 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

argenx logo

About argenx

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.13 out of 5 stars

Medical Sector

1034th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

145th out of 198 stocks

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

argenx (NASDAQ:ARGX) Frequently Asked Questions

Is argenx a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx
or view top-rated stocks.

What stocks does MarketBeat like better than argenx?

Wall Street analysts have given argenx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but argenx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for argenx

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) announced its quarterly earnings data on Friday, May, 14th. The company reported ($0.81) earnings per share for the quarter, topping the Zacks' consensus estimate of ($3.14) by $2.33. The firm had revenue of $167.42 million for the quarter, compared to the consensus estimate of $39.04 million. argenx had a negative net margin of 298.93% and a negative trailing twelve-month return on equity of 50.37%.
View argenx's earnings history

How has argenx's stock been impacted by Coronavirus (COVID-19)?

argenx's stock was trading at $133.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARGX shares have increased by 134.3% and is now trading at $313.58.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARGX?

17 Wall Street analysts have issued 12-month target prices for argenx's stock. Their forecasts range from $250.00 to $430.00. On average, they expect argenx's stock price to reach $332.15 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for argenx
or view top-rated stocks among Wall Street analysts.

Who are argenx's key executives?

argenx's management team includes the following people:
  • Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA, CEO & Exec. Director (Age 49, Pay $1.22M)
  • Mr. Eric Castaldi, Chief Financial Officer (Age 57)
  • Mr. R. Keith Woods, Chief Operating Officer (Age 53)
  • Prof. Hans de Haard, Chief Scientific Officer (Age 61)
  • Mr. Dirk Marcel Leon Beeusaert L.L.M., Gen. Counsel (Age 57)
  • Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 36)
  • Mr. Marc Schorpion, Global Head of HR (Age 63)
  • Dr. David L. Lacey, Advisor (Age 69, Pay $60.82k)
  • Dr. Wim Parys M.D., Chief Medical Officer (Age 61)
  • Ms. Andria Wilk, Global Head of Quality (Age 48)

Who are some of argenx's key competitors?

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (11.29%), Artisan Partners Limited Partnership (5.60%), Baker BROS. Advisors LP (2.18%), Bellevue Group AG (1.86%), Redmile Group LLC (1.66%) and Jennison Associates LLC (1.40%).

Which institutional investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Hillhouse Capital Advisors LTD., Franklin Resources Inc., Redmile Group LLC, Ameriprise Financial Inc., Eaton Vance Management, Renaissance Technologies LLC, and Millennium Management LLC.

Which institutional investors are buying argenx stock?

ARGX stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artisan Partners Limited Partnership, Jennison Associates LLC, BVF Inc. IL, BlackRock Inc., TimesSquare Capital Management LLC, Clearbridge Investments LLC, and Janus Henderson Group PLC.

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $313.58.

How much money does argenx make?

argenx has a market capitalization of $16.09 billion and generates $41.60 million in revenue each year. The company earns $-604,190,000.00 in net income (profit) each year or ($13.30) on an earnings per share basis.

How many employees does argenx have?

argenx employs 336 workers across the globe.

What is argenx's official website?

The official website for argenx is

Where are argenx's headquarters?

argenx is headquartered at Willemstraat 5, Breda P7, 4811 AH.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.